non-alcoholic fatty liver disease.
Conditions
Interventions
Intervention 1: 250 ml/day pomegranate juice for 12 weeks. Intervention 2: 250ml/day orange juice for 12 weeks.
250 ml/day pomegranate juice for 12 weeks
250ml/day orange juice for 12 weeks
Sponsors
Vice-chancellor for Research, Tehran University of Medical Sciences
Gastrointestinal & Liver Disease Research Center (Firoozgar GILDRC)
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: signing written informed consent, age between 30 and 65, diagnosis of non-alcoholic fatty liver disease by fatty infiltration on ultrasound and abnormal serum liver function tests (AST or ALT>30 u/l in men and >20 in women), no smoking, BMI= 25, no pregnancy or lactation, no use of dietary supplements one month prior to enrollment, not having diabetes, renal impairment, acute heart disease, thyroid disease, other form of liver disease (viral or autoimmune hepatitis, metabolic and hereditary liver disease) and any diseases that can affect on body weight, not having severe gaining or losing weight diet in the 3 month prior to the enrollment, no use of medication that could affect body weight in the 3 month prior to the enrollment, no use of drugs that induces steatosis (amidarone, methotrexate, systemic glucocorticoid, tetracycline, tamoxifen, estrogen, anabolic steroids, valporic acid) Exclusion Criteria: those who are not interested in participating in the study, pharmacological treatment with some potential treatment, any diseases which need special treatment, pregnancy during the study period
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AST enzyme. Timepoint: before & after intervention (after 12 weeks intervention. Method of measurement: enzymatic colorimetry kit.;ALT enzyme. Timepoint: before & after intervention (after 12 weeks intervention. Method of measurement: enzymatic colorimetry kit.;Hepatic fat infiltration status. Timepoint: before & after intervention (after 12 weeks intervention. Method of measurement: ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| MDA. Timepoint: before & after intervention (after 12 weeks intervention. Method of measurement: colorimetry kit.;TNF-a. Timepoint: before & after intervention (after 12 weeks intervention. Method of measurement: ELISA.;Total antioxidant capacity. Timepoint: before & after intervention (after 12 weeks intervention. Method of measurement: colorimetry kit.;Fasting Insulin Level. Timepoint: before & after intervention (after 12 weeks intervention). Method of measurement: ELISA.;Fastinf blood sugar. Timepoint: before & after intervention (after 12 weeks intervention). Method of measurement: enzymatic colorimetry kit.;HOMA-R. Timepoint: before & after intervention (after 12 weeks intervention). Method of measurement: Calculating.;LDL-C. Timepoint: before & after intervention (after 12 weeks intervention). Method of measurement: immunoturbidimetry.;HDL-C. Timepoint: before & after intervention (after 12 weeks intervention). Method of measurement: immunoturbidimetry.;Triglyceride. Timepoint: before & after intervention (after 12 weeks intervention). Method of measurement: colorimetry.;Total colestrol. Timepoint: before & after intervention (after 12 weeks intervention). Method of measurement: colorimetry.;Blood pressure. Timepoint: before & after intervention (after 12 weeks intervention). Method of measurement: sphygmomanometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Farzad Shidfar
Faculty of Public Health of Tehran University of Medical Sciences
Outcome results
None listed